Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103
Recruiting
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
05/28/2025
Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +52 locations
Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Register for Updates
RESPECT: (REsearching Stigma in PEdiatric Cancer Tool)
NCT06470230
Recruiting
Researchers want to learn more about the way stigma affects children with cancer and their caregivers. They want to develop two clinical tools to identify and measure stigma in the pediatric cancer population within culturally diverse global settings of the United States, Guatemala, and Jordan. Primary Objectives * Develop two clinical tools that can be used to identify and measure stigma as experienced by (1) pediatric oncology patients/survivors and (2) their guardians/caregivers in cultural... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
05/28/2025
Locations: Washington University School of Medicine in St. Louis, Saint Louis, Missouri +3 locations
Conditions: Stigma
Register for Updates
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2025
Locations: Digestive Health Specialists /ID# 266216, Dothan, Alabama +210 locations
Conditions: Crohn's Disease
Register for Updates
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3
NCT06595030
Recruiting
Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/28/2025
Locations: Icahn School of Medicine at Mount Sinai, Menands, New York +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
NCT06659029
Recruiting
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/28/2025
Locations: Research Site, Las Vegas, Nevada
Conditions: Systemic Lupus Erythematosus
Register for Updates
Community-based Implementation of Adapted STAC
NCT06689930
Recruiting
This study is being done to adapt the Staying Healthy After Childbirth (STAC) intervention for implementation among Black Women and Birthing Persons (WBP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Blood Pressure, Hypertension, Pregnancy Related, Health Equity
Register for Updates
Onyx™ Liquid Embolic IDE Clinical Study
NCT06742801
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/28/2025
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado +1 locations
Conditions: Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer, Hemorrhage
Register for Updates
Neuroimaging of Escitalopram in Autism Spectrum Disorder
NCT06826326
Recruiting
The goal of this clinical trial is to evaluate the acute effects of escitalopram (Lexapro®) on select brain networks during task-based functional magnetic resonance imaging (fMRI) in adolescent individuals with autism spectrum disorder (ASD). We hope to learn more about the acute effects of escitalopram and how it might be used to treat inflexible thinking or rigid-compulsive behavior that can be associated with restricted and repetitive behaviors in adolescents with ASD. Participants will: *... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/28/2025
Locations: Hoglund Biomedical Imaging Center, Kansas City, Kansas
Conditions: Autism Spectrum Disorder
Register for Updates
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutiki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Newport Huntington Medical Group /ID# 272764, Huntington Beach, California +8 locations
Conditions: Psoriatic Arthritis
Register for Updates
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737
Recruiting
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Cancer and Hematology Centers of Western Michigan ( Site 0015), Grand Rapids, Michigan +8 locations
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
A Positive Food Parenting Intervention to Promote Healthy Growth in Children at Risk for Obesity
NCT06981429
Recruiting
This study is the pilot of a 12 - week positive food parenting intervention focused on structure-based and autonomy promoting practices. The intervention aims to give parents the tools to promote healthy child growth and improve diet quality. The investigators are piloting to assess feasibility and efficacy of the intervention through examining participant retention, impact on parent feeding practices, and impact on parent and child diet quality.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
05/28/2025
Locations: State University of New York at Buffalo, South Campus, Buffalo, New York
Conditions: Pediatric Obesity, Nutrition Disorder
Register for Updates
Use of Cysteamine in the Treatment of Cystinosis
NCT00359684
Recruiting
Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. The cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle. The drug cysteamine (Cystagon; Pro... Read More
Gender:
ALL
Ages:
Between 1 week and 115 years
Trial Updated:
05/28/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cystinosis
Register for Updates